Similar syndromes are now recognized as class effects of targeted therapies against key driver mutations in AML—including FLT3 TKIs in FLT3-mutant AML, IDH inhibitors in IDH-mutant AML, and, more recently, menin inhibitors in KMT2A-rearranged AML [38]. The gene discussed is MEN1; the disease is acute myeloid leukemia.